Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases

Current Cancer Drug Targets

Volumn 1, Issue 3, 2001, Pages 211-230

  Mercatante, D R ^a,b   Sazani, P ^a,b   Kole, R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; ANIMAL; BETA THALASSEMIA; CYSTIC FIBROSIS; DRUG DESIGN; DRUG EFFECT; GENETICS; HUMAN; MUSCULAR DYSTROPHY; NEOPLASM; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; ANIMALS; ANTINEOPLASTIC AGENTS; BETA-THALASSEMIA; CYSTIC FIBROSIS; DRUG DESIGN; GENES, TUMOR SUPPRESSOR; HUMANS; MUSCULAR DYSTROPHIES; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENES; RNA, MESSENGER;

EID: 0035502474     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009013334124     Document Type: Article

References (183)

1. Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C. Zody, M. C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle M.; FitzHugh, W.; Funke, R.; Gage, D.; Harris, K. Heaford, A.; Rowland, J.; Kann, L.; Lehoczky, J. LeVine, R.; McEwan, P.; McKernan, K.; Meldrim, J. Mesirov, J.P.; Miranda, C.; Morris, W.; Naylor, J., et al. Initial Sequencing and Analysis of the Human Genome Nature 2001, 409, 860-921.
2. Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W. Mural, R. J.; Sutton, G. G.; Smith, H. O.; Yandell, M. Evans, C. A.; Holt, R. A.; Gocayne, J. D.; Amanatides, P. Ballew, R. M.; Huson, D. H.; Wortman, J. R.; Zhang, Q. Kodira, C. D.; Zheng, X. H.; Chen, L.; Skupski, M. Subramanian, G.; Thomas, P. D.; Zhang, J.; Gabor-Miklos, G. L.; Nelson, C., et al. The Sequence of the Human Genome. Science 2001, 297, 1304-1351.
3. Graveley, B. R. Alternative Splicing: Increasing Diversity in the Proteomic World. Trends Genet. 2001, 17, 100-107.
4. Smith, C. W.; Valcarcel, J. Alternative Pre-mRNA Splicing: The Logic of Combinatorial Control. Trends Biochem. Sei. 2000, 25, 381-388.
5. Krainer, A. R. Eukaryptic mRNA Processing. In Frontiers in Molecular Biology; Harnes, B. D.; Glover, D. M., Eds.; Oxford University Press: New York, 1997.
6. Stickeier, E.; Kittrell, F.; Medina, D.; Berget, S. M. Stage-Specific Changes in Sr Splicing Factors and Alternative Splicing in Mammary Tumorigenesis. Oncogene 1999, 18, 3574-3582.
7. Jin, W.; McCutcheon, I. E.; Fuller, G. N.; Huang, E. S.; Cote, G. J. Fibroblast Growth Factor Receptor-1 Alpha-Exon Exclusion and Polypyrimidine Tract-Binding Protein in Glioblastoma Multiforme Tumors. Cancer Res. 2000,60, 1221-1224.
8. Hartmann, A. M.; Nayler, O.; Schwaiger, F. W.; Obermeier, A.; Stamm, S. The Interaction and Colocalization of Sam68 with the Splicing-Associated Factor YT521-B in Nuclear Dots is Regulated by the Src Family Kinase p59(fyn). Mol. Biol. Cell 1999, 10, 3909-3926.
9. Xie, J.; Black, D. L. A CaMK. IV Responsive RNA Element Mediates Depolarization-Induced Alternative Splicing of Ion Channels. Nature 2001, 410, 936-939.
10. Turpin, E.; Dalle, B.; de Roquancourt, A.; Plassa, L. F.; Marty, M.; Janin, A.; Beuzard, Y.; de The, H. Stress-Induced Aberrant Splicing of TSG101: Association to High Tumor Grade and p53 Status in Breast Cancers. Oncogene 1999, 18, 7834-7837.
11. Lee, M. P.; Feinberg, A. P. Aberrant Splicing but not Mutations of TSG101 in Human Breast Cancer. Cancer Res. 1997, 57, 3131-3134.
12. McKeehan, W. L.; Wang, F.; Kan, M. The Heparan Sulfate-Fibroblast Growth Factor Family: Diversity of Structure and Function. Prog. Nucleic Acid Res. Mol. Biol. 1998, 59, 135-376.
13. Galzie, Z.; Kinsella, A. R.; Smith, J.A. Fibroblast Growth Factors and their Receptors. Biochem. Cell. Biol. 1997, 75, 669-685.
14. Johnson, D. E.; Williams, L. T. Structural and Functional Diversity in the FGF Receptor Multigene Family. Adv. Cancer Res. 1993, 60, 1-41.
15. Carstens, R. P.; Eaton, J. V.; Krigman, H. R.; Walther, P. J.; Garcia-Blanco, M. A. Alternative Splicing of Fibroblast Growth Factor Receptor 2 (FGF-R2) in Human Prostate Cancer. Oncogene 1997,15, 3059-3065.
16. Kwabi-Addo, B.; Ropiquet, F.; Giri, D.; Ittmann, M. Alternative Splicing of Fibroblast Growth Factor Receptors in Human Prostate Cancer. Prostate 2001, 46, 163-172.
17. Carstens, R. P.; Wagner, E.J.; Garcia-Blanco, M.A. An Intronic Splicing Silencer Causes Skipping of the Illb Exon of Fibroblast Growth Factor Receptor 2 through Involvement of Polypyrimidine Tract Binding Protein. Mol. Cell Biol. 2000, 20, 7388-7400.
18. Deng, C.; Wynshaw-Boris, A.; Zhou, F.; Kuo, A.; Leder, P. Fibroblast Growth Factor Receptor 3 is a Negative Regulator of Bone Growth. Cell 1996, 84, 911-921.
19. Jang, J. H.; Shin, K. H.; Park, Y. J.; Lee, R. J.; McKeehan, W. L.; Park, J. G. Novel Transcripts of Fibroblast Growth Factor Receptor 3 Reveal Aberrant Splicing and Activation of Cryptic Splice Sequences in Colorectal Cancer. Cancer Res. 2000, 60, 4049-4052.
20. Takaishi, S.; Sawada, M.; Morita, Y.; Seno, H.; Fukuzawa, H.; Chiba, T. Identification of a Novel Alternative Splicing of Human FGF Receptor 4: SolubleForm Splice Variant Expressed in Human Gastrointestinal Epithelial Cells. Biochem. Biophys. Res. Commun. 2000, 267, 658-662.
21. Lee, S. B.; Haber, D. A. Wilms Tumor and the WT1 Gene. Exp. Cell Res. 2001, 264, 74-99.
22. Renshaw, J.; King-Underwood, L.; Pritchard-Jones, K. Differential Splicing of Exon 5 of the Wilms Tumour (WTI) Gene. Genes Chromosomes Cancer 1997, 19, 256-266.
23. Pritchard-Jones, K.; King-Underwood, L. The Wilms Tumour Gene WTI in Leukaemia. Lenk. Lymphoma 1997, 27, 207-220.
24. Iben, S.; Royer-Pokora, B. Analysis of Native WTI Protein from Frozen Human Kidney and Wilms1 Tumors. Oncogene 1999, 18, 2533-2536.
25. Richard, D.J.; Schumacher, V.; Royer-Pokora, B.; Roberts, S. G. Par4 is a Coactivator for a Splice IsoformSpecific Transcriptional Activation Domain in WTI. Genes Dey. 2001, 15, 328-339.
26. Zhang, H.; Tombline, G.; Weber, B.L. BRCA1, BRCA2, and DNA Damage Response: Collision or Collusion? Cell 1998, 92, 433-436.
27. Lu, M.; Conzen, S. D.; Cole, C. N.; Arrick, B. A. Characterization of Functional Messenger RNA Splice Variants of BRCA1 Expressed in Nonmalignant and Tumor-Derived Breast Cells. Cancer Res. 1996, 56, 4578-4581.
28. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P. A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L. M.; Ding, W.; et al. A.Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science. 1994, 266, 66-71.
29. Thakur, S.; Zhang, H. B.; Peng, Y.; Le, H.; Carroll, B.; Ward, T.; Yao, J.; Farid, L. M.; Couch, F. J.; Wilson, R. B.; Weber, B. L. Localization of BRCA1 and a Splice Variant Identifies the Nuclear Localization Signal. Mol. Cell Biol. 1997, 17, 444-452.
30. Orban, T. I.; Olah, E. Expression Profiles of BRCA1 Splice Variants in Asynchronous and in Gl/S Synchronized Tumor Cell Lines. Biochem. Biophys. Res. Commun. 2001, 250, 32-38.
31. Bieche, I.; Lidereau, R. Increased Level of Exon 12 Alternatively Spliced BRCA2 Transcripts in Tumor Breast Tissue Compared with Normal Tissue. Cancer Res. 1999, 59, 2546-2550.
32. Hsieh, H. F.; Yu, J. C.; Ho, L. I.; Chiu, S. C.; Harn, H. J. Molecular Studies into the Role of CD44 Variants in Metastasis in Gastric Cancer. Mol. Pathol. 1999, 52, 2528.
33. Sneath, R. J.; Mangham, D. C. The Normal Structure And Function Of CD44 and its Role in Neoplasia. Mol. Pathol. 1998, 51, 191-200.
34. Wallach, S. B.; Friedmann, A.; Naor, D. The CD44 Receptor of the Mouse LB T-Cell Lymphoma: Analysis of the Isoform Repertoire and Ligand Binding Properties by Reverse-Transcriptase Polymerase Chain Reaction and Antisense Oligonucleotides. Cancer Detect. Prev. 2000. 24, 33-45.
35. Herrera-Gayol, A.; Jothy, S. Adhesion Proteins in the Biology of Breast Cancer: Contribution of CD44. Exp. Mol. Pathol. 1999, 66, 149-156.
36. Wittig, B. M.; Goebel, R.; Weg-Remers, S.; Pistorius, G.; Feifei, G.; Zeitz, M.; Stallmach, A. Stage-specific Alternative Splicing of CD44 and Alpha 6 Beta 1 Integrin in Colorectal Tumorigenesis. Exp. Mol. Pathol. 2001. 70, 96-102.
37. Emmert, S.; Schneider, T. D.; Khan, S. G.; Kraemer, K. H. The Human XPG Gene: Gene Architecture, Alternative Splicing and Single Nucleotide Polymorphisms. Nucleic Acids Res. 2001, 29, 1443-1452.
38. Cheng, L.; Spitz, M. R.; Hong, W. K.; Wei, Q. Reduced Expression Levels of Nucleotide Excision Repair Genes in Lung Cancer: A Case-Control Analysis. Carcinogenesis 2000, 21, 1527-1530.
39. Wei, Q.; Cheng, L.; Hong, W. K.; Spitz, M. R. Reduced DNA Repair Capacity in Lung Cancer Patients. Cancer Res. 1996, 56, 4103-4107.
40. Scala, S.; Wosikowski, K.; Giannakakou, P.; Valle, P.; Biedler, J. L.; Spengler, B. A.; Lucarelli, E.; Bates, S. E.; Thiele, C. J. Brain-Derived Neurotrophic Factor Protects Neuroblastoma Cells from Vinblastine Toxicity. Cancer Res. 1996, 56, 3737-3742.
41. .Middlemas, D. S.; Kihl, B. K.; Zhou, J.; Zhu, X. BrainDerived Neurotrophic Factor Promotes Survival and Chemoprotection of Human Neuroblastoma Cells. J. Biol. Chem. 1999, 274, 16451-16460.
42. Aoyama, M.; Asai, K.; Shishikura, T.; Kawamoto, T.; Miyachi, T.; Yokoi, T.; Togari, H.; Wada, Y.; Kato, T.; Nakagawara, A. Human Neuroblastomas with Unfavorable Biologies Express High Levels of BrainDerived Neurotrophic Factor mRNA and a Variety of its Variants. Cancer Lett. 2001,164, 51-60. .
43. Jiang, Z. H.; Wu, J. Y. Alternative Splicing and Programmed Cell Death. Proc. Soc. Exp. Biol. Med. 1999, 220, 64-72.
44. Wang, L.; Miura, M.; Bergeron, L.; Zhu, H.; Yuan, J. Ich1, an Ice/ced-3-Related Gene, Encodes both Positive and Negative Regulators of Programmed Cell Death. Cell 1994, 78, 739-750.
45. Fujimura, M.; Kasahara, K.; Shirasaki, H.; Heki, U.; Iwasa, K.; Ueda, A.; Matsuda, T. Up-regulation of ICH1L Protein by Thromboxane A2 Antagonists Enhances Cisplatin-Induced Apoptosis in Non-Small-Cell LungCancer Cell Lines. J. Cancer Res. Clin. Oncol. 1999, 725, 389-394.
46. Droin, N.; Rebe, C.; Bichat, F.; Hammann, A.; Bertrand, R.; Solary, E. Modulation of Apoptosis By Procaspase-2 Short Isoform: Selective Inhibition of Chromatin Condensation, Apoptotic Body Formation and Phosphatidylserine Externalization. Oncogens 2001, 20, 260-269.
47. Vaux, D. L.; Cory, S.; Adams, J. M. Bcl-2 Gene Promotes Haemopoietic Cell Survival and Cooperates With C-Myc to Immortalize Pre-B Cells. Nature 1988, 335, 440-442.
48. DiPaola, R. S.; Aisner, J. Overcoming Bcl-2- and p53-Mediated Resistance in Prostate Cancer. Semin. Oncol. 1999,26, 112-116.
49. O'Connell, J.; Bennett, M. W.; Nally, K.; Houston, A.; O'Sullivan, G. C.; Shanahan, F. Altered Mechanisms of Apoptosis in Colon Cancer: Fas Resistance and Counterattack in the Tumor-Immune Conflict. Ann. N. Y. Acad. Sei. 2000, 910, 178-192; discussion 193-195.
50. Tsujimoto, Y.; Croce, C. M. Analysis of the Structure, Transcripts, and Protein Products of Bcl-2, The Gene Involved in Human Follicular Lymphoma. Proc. Natl. Acad. Sei. U. S. A. 1986, 83, 5214-5218.
51. Zhang, G. J.; Kimijima, I.; Onda, M.; Kanno, M.; Sato, H.; Watanabe, T.; Tsuchiya, A.; Abe, R.; Takenoshita, S. Tamoxifen-Induced Apoptosis in Breast Cancer Cells Relates to Down- Regulation of Bcl-2, but not Bax and Bcl-x(L), without Alteration of p53 Protein Levels. Clin. Cancer Res. 1999,5, 2971-2977.
52. Boise, L.H.; Gonzalez-Garcia, M.; Postema, C. E.; Ding, L.; Lindsten, T.; Turka, L. A.; Mao, X.; Nùnez, G.; Thompson, C.B. Bcl-x, a Bcl-2-Related Gene that Functions as a Dominant .Regulator of Apoptotic Cell Death. Cell 1993, 74, 597-608.
53. Krajewska, M.; Krajewski, S.; Epstein, J. I.; Shabaik, A.; Sauvageot, J.; Song, K.; Kitada, S.; Reed, J. C. Immunohistochemical. Analysis of Bcl-2, Bax, Bcl-x, and Mcl-1 Expression in Prostate Cancers. Am. J. Pathol. 1996,148, 1567-1576.
54. Marone, M.; Scambia, G.; Mozzetti, S.; Ferrandina, G.; lacovella, S.; De Pasqua, A.; Benedetti-Panici, P.; Mancuso, S. Bcl-2, Bax, Bcl-xL, And Bcl-xS Expression in Normal and Neoplastic Ovarian Tissues. Clin. Cancer Res. 1998, 4, 517-524.
55. Nuessler, V.; Stotzer, O.; Gullis, E.; Pelka-Fleischer, R.; Pogrebniak, A.; Gieseler, F.; Wilmanns, W. Bcl-2, bax and bcl-xL Expression in Human Sensitive and Resistant Leukemia Cell Lines. Leukemia 1999, 13, 1864-1872.
56. Simonian, P. L.; Grillot, D. A.; Nunez, G. Bcl-2 and BclxL can Differentially Block Chemotherapy-Induced Cell Death. Blood 1997, 90, 1208-1216.
57. Han, J. S.; Nunez, G.; Wicha, M. S.; Clarke, M. F. Targeting Cancer Cell Death with a Bcl-XS Adenovirus. Springer Semin. Immunopathol. 1998, 19, 279-288.
58. Taylor, J. K.; Zhang, Q. Q.; Monia, B. P.; Marcusson, E. G.; Dean, N. M. Inhibition of Bcl-xL Expression Sensitizes Normal Human Keratinocytes and Epithelial Cells to Apoptotic Stimuli. Oncogene 1999,18, 4495-4504.
59. Sumantran, V. N.; Ealovega, M. W.; Nunez, G.; Clarke, M. F.; Wicha, M. S. Overexpression of Bcl-XS Sensitizes MCF-7 Cells to Chemotherapy-Induced Apoptosis. Cancer Res. 1995,55, 2507-2510.
60. Ray, S.; Bullock, G.; Nunez, G.; Tang, C.; Ibrado, A. M.; Huang, Y.; Bhalla, K. Enforced Expression of Bcl-XS Induces Differentiation and Sensitizes Chronic Myelogenous Leukemia-Blast Crisis K562 Cells to 1-Beta-D-Arabinofuranosylcytosine-Mediated Differentiation and Apoptosis. Cell Growth Differ. 1996, 7, 1617-1623.
61. O'Connor, L.; Strasser, A.; O'Reilly, L. A.; Hausmann, G.; Adams, J. M.; Cory, S.; Huang, D. C. Bim: A Novel Member of the Bcl-2 Family that Promotes Apoptosis. EMBO J. 1998, 17, 384-395.
62. Oltvai, Z. N.; Milliman, C. L.; Korsmeyer, S. J. Bcl-2 Heterodimerizes In Vivo With A Conserved Homolog, Bax, that Accelerates Programmed Cell Death. Cell 1993, 74, 609-619.
63. VVu, J.; Shao, Z. M.; Shen, Z. Z.; Lu, J.S.; Han, Q. X.; Fontana, J. A.; Barsky, S. H. Significance of Apoptosis and Apoptotic-Related Proteins, Bcl-2, and Bax in Primary Breast Cancer. Breast J. 2000, 6, 44-52.
64. Zhou, M.; Demo, S. D.; McClure, T. N.; Crea, R.; Bitler, C. M. A Novel Splice Variant of the Cell Death-Promoting Protein BAX. J. Biol. Chem. 1998,273, 11930-11936.
65. Apte, S. S.; Mattel, M. G.; Olsen, B. R. Mapping of the Human BAX Gene to Chromosome 19q13.3-Q13.4 and Isolation of a Novel Alternatively Spliced Transcript, BAX Delta Genomics 1995, 26, 592-594.
66. Patel, V.; Ensley, J. F.; Gutkind, J. S.; Yeudall, W. A. Induction of Apoptosis in Head-and-Neck Squamous Carcinoma Cells by Gamma-Irradiation and Bleomycin is p53-Independent. Int. J. Cancer 2000, 88, 737-743.
67. Messineo, C.; Jamerson, M. H.; Hunter, E.; Braziel, R.; Bagg, A.; Irving, S. G.; Cossman, J. Gene Expression by Single Reed-Sternberg Cells: Pathways of Apoptosis and Activation. Blood 1998, 91, 2443-2451.
68. Schmitt, E.; Paquet, C.; Beauchemin, M.; Dever-Bertrand, J.; Bertrand, R. Characterization of Bax-Sigma, a Cell Death-Inducing Isoform of Bax. Blochem. Biophys. Res. Commun. 2000, 270, 868-879.
69. Ruberti, G.; Cascino, I.; Papoff, G.; Eramo, A. Fas Splicing Variants and their Effect on Apoptosis. Adv. Exp. Med. Biol. 1996, 406, 125-134.
70. Screaton, G.R.; Xu, X.N.; Olsen, A.L.; Cowper, A.E.; Tan, R.; McMichael, A.J.; Bell, J. I. LARD: A New Lymphoid-Specific Death Domain Containing Receptor Regulated by Alternative Pre-mRNA Splicing. Proc. Natl. Acad. Sei. U. S. A. 1997, 94, 4615-4619.
71. Luan, X.; Shi, G.; Zohouri, M.; Paradee, W.; Smith, D. L; Decker, H. J.; Cannizzaro, L. A. The FHIT Gene is Alternatively Spliced in Normal Kidney and Renal Cell Carcinoma. Oncogens 1997, 15, 79-86.
72. Sato, H.; Hiyama, K.; Ishioka, S.; Maeda, H.; Yamakido, M. Alternative Splicing, but not Allelic Loss, of the FHIT Gene Increases with Development of Lung Cancer. Int. J. Oncol. 1999, 15, 81-88.
73. Kaelin, W. G., Jr. The p53 Gene Family. Oncogene 1999, 18, 7701-7705.
74. Kaghad, M.; Bonnet, H.; Yang, A.; Creancier, L.; Biscan, J.C.; Valent, A.; Minty, A.; Chalon, P.; Lelias, J. M.; Dumont, X.; Ferrara, P.; McKeon, F.; Caput, D. Monoallelically Expressed Gene Related to p53 at Ip36, a Region Frequently Deleted in Neuroblastoma and other Human Cancers. Cell 1997, 90, 809-819.
75. Fillippovich, I.; Sorokina, N.; Gatei, M.; Haupt, Y.; Hobson, K.; Moallem, E.; Spring, K.; Mould, M.; McGuckin, M. A.; Lavin, M. F.; Khanna, K. K. Transactivation-Deficient p73alpha (p73Deltaexon2) Inhibits Apoptosis and Competes with p53. Oncogene 2001,20,514-522.
76. Lohrum, M. A.; Vousden, K. H. Regulation and Activation of p53 and its Family Members. Cell Death Differ. 1999, 6, 1162-1168.
77. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 Promotes the Rapid Degradation of p53. Nature 1997, 387, 296-299.
78. Kubbutat, M. H.; Jones, S. N.; Vousden, K. H. Regulation of p53 Stability by MDM2. Nature 1997, 387, 299-303.
79. Oliner, J. D.; Pietenpol, J. A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K. W.; V.ogelstein, B. Oncoprotein MDM2 Conceals the Activation Domain of Tumour Suppressor p53. Nature 1993, 362, 857-860.
80. Matsumoto, R.; Tada, M.; Nozaki, M.; Zhang, C. L.; Sawamura, Y.; Abe, H. Short Alternative Splice Transcripts of the MDM2 Oncogene Correlate To Malignancy in Human Astrocytic Neoplasms. Cancer Res. 1998, 58, 609-613.
81. Sigalas, I.; Calvert, A. H.; Anderson, J. J.; Neal, D. E. Lunée, J. Alternatively Spliced mdm2 Transcripts with Loss of p53 Binding Domain Sequences: Transforming Ability and Frequent Detection in Human Cancer. Nat. Med.1996,2, 912-917.
82. Lukas, J.; Gao, D. Q.; Keshmeshian, M.; Wen; W. H.; Tsao-Wei, D.; Rosenberg, S.; Press, M. F. Alternative and Aberrant Messenger RNA Splicing of the mdm2 Oncogene in Invasive Breast Cancer. Cancer Res. 2001, 61, 3212-3219.
83. Barte!, F.; Meye, A.; Wuri, P.; Kappler, M.; Bache, M.; Lautenschlager; C.; Grunbaum, U.; Schmidt, H.; Taubert, H. Amplification of the MDM2 gene, but not Expression of Splice Variants of MDM2 MRNA, is Associated with Prognosis in Soft Tissue Sarcoma./J. J. Cancer2001, 95, 168-175.
84. Keppler, D.; Sloane, B. F. Cathepsin B: Multiple Enzyme Forms from a Single Gene and their Relation to Cancer. Enzyme Protein 1996, 49, 94-105.
85. Yano, M.; Hirai, K.; Naito, Z.; Yokoyama, M.; Ishiwata, T.; Shiraki, Y.; Inokuchi, M.; Asano, G. Expression of Cathepsin B and Cystatin C in Human Breast Cancer. Surg. Today 2001, 31, 385-389.
86. Poole, J. C.; Andrews, L. G.; Tollefsbol, T. O. Activity, Function, and Gene Regulation of the Catalytic Subunit ofTelomerase(hTERT). Gene 2001, 269, 1-12.
87. Kanaya, T.; Kyo, S.; Hamada, K.; Takakura, M.; Kitagawa, Y.; Harada, H.; Inoue, M. Adenoviral Expression of p53 Represses Telomerase Activity through Down-Regulation Of Human Telomerase Reverse Transcriptase Transcription. Clin. Cancer Res. 2000,0, 1239-1247.
88. Nakamura, T. M.; Morin, G. B.; Chapman, K. B.; Weinrich, S. L.; Andrews, W. H.; Lingner, J.; Harley, C. B.; Cech, T. R. Telomerase Catalytic Subunit Homologs from Fission Yeast and Human. Science 1997, 277, 955-959.
89. Gorham, H.; Yoshida, K.; Sugino, T.; Marsh, G.; Manek, S.; Charnock, M.; Tarin, D.; Goodison, S. Telomerase Activity in Human Gynaecological Malignancies. J. Clin. Pathol. 1997, 50, 501-504.
90. Kyo, S.; Kanaya, T.; Ishikawa, H.; Ueno, H.; Inoue, M. Telorherase Activity in Gynecological Tumors. Clin. Cancer Res. 1996, 2, 2023-2028.
91. Kyo, S.; Kanaya, T.; Takakura, M.; Tanaka, M.; Yamashita, A.; Inoue, H.; Inoue, M. Expression of Human Telomerase Subunits in Ovarian Malignant, Borderline and Benign Tumors. Int. J. Cancer 1999, 80, 804-809.
92. Kyo, S.; Kanaya, T.; Takakura, M.; Tanaka, M.; Inoue, M. Human Telomerase Reverse Transcriptase as a Critical Determinant of Telomerase Activity in Normal and Malignant Endometrial Tissues. Int. J. Cancer 1999, 80, 60-63.
93. Saito, T.; Schneider, A.; Martel, N.; Mizumoto, H.; Bulgay-Moerschel, M.; Kudo, R.; Nakazawa, H. Proliferation-Associated Regulation of Telomerase Activity in Human Endometrium and its Potential Implication in Early Cancer Diagnosis. Biochem. Biophys. Res. Commun. 1997,231, 610-614.
94. Ulaner, G. A.; Hu, J. F.; Vu, T. H.; Oruganti, H.; Giudice, L.C.; Hoffman, A. R. Regulation of Telomerase by Alternate Splicing of Human Telomerase Reverse Transcriptase (hTERT) in Normal and Neoplastic Ovary, Endometrium and Myometrium. Int. J. Cancer 2000, 85, 330-335.
95. Frearson, J. A.; Alexander, D. R. The Role of Phosphotyrosine Phosphatases in Haematopoietic Cell Signal Transduction. Bioessays 1997, 19, 417-427.
96. Yi, T. L.; Cleveland, J. L.; Ihle, J. N. Protein Tyrosine Phosphatase Containing SH2 Domains: Characterization, Preferential Expression in Hematopoietic Cells, and Localization to Human Chromosome 12pl2-pl3. Mol. Cell Biol. 1992, 12, 836-846.
97. Beghini, A.; Ripamonti, C. B.; Peterlongo, P.; Roversi, G.; Cairoli, R.; Morra, E.; Larizza, L. RNA Hyperediting and Alternative Splicing of Hematopoietic Cell Phosphatase (PTPN6) Gene in Acute Myeloid Leukemia. Hum. Mol. Genet. 2000, 9, 2297-2304.
98. Leppa, S.; Bohmann, D. Diverse Functions of JNK Signaling and c-Jun in Stress Response and Apoptosis. Oncogene 1999, 18, 6158-6162.
99. Best, F.; McKay, R.; Bost, M.; Potapova, O.; Dean, N. M.; Mercola, D. The Jun Kinase 2 Isoform is Preferentially Required for Epidermal Growth FactorInduced Transformation of Human A549 Lung Carcinoma Cells. Mol. Cell Biol. 1999,19, 1938-1949.
100. Butterfield, L.; Storey, B.; Maas, L.; Heasley, L. E. c-Jun NH2-Terminal Kinase Regulation of the Apoptotic Response of Small Cell Lung Cancer Cells to Ultraviolet Radiation. J. Biol. Chem. 1997,272, 10110-10116.
101. Gupta, S.; Barrett, T.; Whitmarsh, A. J.; Cavanagh, J.; Sluss, H. K.; Derijard, B.; Dàvis, R. J. Sélective Interaction of JNK Protein Kinase Isoforms with Transcription Factors. EMBO J. 1996,15, 2760-2770.
102. Spengler, D.; Villalba, M.; Hoffmann, A.; Pantaloni, C.; Houssami, S.; Bockaert, J.; Journot, L. Regulation of Apoptosis and Cell Cycle Arrest by Zacl, a Novel Zinc Finger Protein Expressed in the Pituitary Gland and the Brain. EMBO J. 1997,16, 2814-2825.
103. Bilanges, B.; Varrault, A.; Basyuk, E.; Rodriguez, C.; Mazumdar, A.; Pantaloni, C.; Bockaert, J.; Theillet, C.; Spengler, D.; Journot, L. Loss of Expression of the Candidate Tumor Suppressor Gene ZAC in Breast Cancer Cell Lines and Primary Tumors. Oncogens 1999, 18, 3979-3988.
104. Bilanges, B.; Varrault, A.; Mazumdar, A.; Pantaloni, C.; Hoffmann, A.; Bockaert, J.; Spengler, D.; Journot, L. Alternative Splicing of the Imprinted Candidate Tumor Suppressor Gene ZAC Regulates its Antiproliferative and DNA Binding Activities. Oncogene 2001, 20, 1246-1253.
105. Colomer, R.; Shamon, L.A.; Tsai, M.S.; Lupu, R. Herceptin: from the Bench to the Clinic. Cancer Invest. 2001,19, 49-56.
106. Scott, G. K.; Robles, R.; Park, J. wl; Montgomery, P. A.; Daniel, J.; Holmes, W. E.; Lee, J.; Keller, G. A.; Li, W. L.; Fendly, B. M.; et al. A Truncated Intracellular HER2/Neu Receptor Produced by Alternative RNA Processing Affects Growth of Human Carcinoma Cells. Afol. Cell Biol. 1993, 13, 2247-2257.
107. Doherty, J. K.; Bond, C.; Jardim, A.; Adelman, J. P.; Clinton, G. M. The HER-2/neu Receptor Tyrosine Kinase Gene Encodes a Secreted Autoinhibitor. Proc. Natl. Acad. Sei. U. S. A. 1999, 96, 10869-10874.
108. Aigner, A.; Juhl, H.; Malerczyk, C.; Tkybusch, A.; Benz, C. C.; Czubayko, F. Expression of a Truncated 100 kDa HER2 Splice Variant Acts as an Endogenous Inhibitor of Tumour Cell Proliferation. Oncogene 2001, 20, 2101-2111.
109. Saaristo, A.; Karpanen, T.; Alitalo, K. Mechanisms of Angiogenesis aand their Use in the Inhibition of Tumor Growth and Metastasis. Oncogene 2000, 19, 6122-6129.
110. Burchardt, T.; Burchardt, M.; Chen, M. W.; Buttyan, R.; de la Taille, A.; Shabsigh, A.; Shabsigh, R. Expression of VEGF Splice Variants 144/145 and 205/206 in Adult Male Tissues. 1UBMB Life 1999, 48, 405-408.
111. [Ill] . Cheung, N.; Wong, M. P.; Yuen, S. T.; Leung, S. Y.; Chung, L. P. Tissue-Specific Expression Pattern of Vascular Endothelial Growth Factor Isoforms in the Malignant Transformation of Lung and Colon. Hum. Pathol. 1998, 29, 910-914.
112. Wellmann, S.; Taube, T.; Paal, K.; Graf, V. E. H.; Geilen, W.; Seifert, G.; Eckert, C.; Henze, G.; Seeger, K. Specific Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor (VEGF) Splice Variants by LightCycler Technology. Clin. Chem. 2001, 47, 654-660.
113. Jeltsch, M.; Kaipainen, A.; Joukov, V.; Meng, X.; Lakso, M.; Rauvala, H.; Swartz, M.; Fukumura, D.; Jain, R. K.; Alitalo, K. Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice. Science 1997,275, 1423-1425.
114. Petrova, T. V.; Makinen, T.; Alitalo, K. Signaling via Vascular Endothelial Growth Factor Receptors. Exp Cell Res. 1999, 253, 117-130.
115. Gunningham, S. P.; Currie, M. J.; Han, C.; Robinson, B. A.; Scott, P. A.; Harris, A. L.; Fox, S. B. The Short Form of the Alternatively Spliced flt-4 but not its Ligand Vascular Endothelial Growth Factor C is Related to Lymph Node Metastasis in Human Breast Cancers. Clin. Cancer Res. 2000, 6, 4278-4286.
116. Gasdaska, P. Y.; Oblong, J. E.; Cotgreave, I. A.; Powis, G. The Predicted Amino Acid Sequence of Human Thioredoxin is Identical to that of the Autocrine Growth Factor Human Adult T-Cell Derived Factor (ADF): Thioredoxin mRNA is Elevated in Some Human Tumors. Biochim. Biophys. Ada 1994,1218, 292-296.
117. Berggren, M.; Gallegos, A.; Gasdaska, J. R.; Gasdaska, P. Y.; Warneke, J.; Powis, G. Thioredoxin and Thioredoxin Reductase Gene Expression in Human Tumors and Cell Lines, and the Effects of Serum Stimulation and Hypoxia Anticancer Res. 1996,16, 3459-3466.
118. Berggren, M. M.; Powis, G. Alternative Splicing is Associated with Decreased Expression of the Redox Proto-Oncogene Thioredoxin-1 in Human Cancers. Arch Biochem. Biophys. 2001, 389, 144-149.
119. Mercatante, D. R.; Bortner, C. D.; Cidlowski, J. A.; Kole, R. Modification of Alternative Splicing of Bcl-x PremRNA in Prostate and Breast Cancer Cells: Analysis of Apoptosis and Cell Death. J. Biol. Chem. 2001, 276, 16411-16417.
120. Taylor, J. K.; Zhang, Q. Q.; Wyatt, J. R.; Dean, N. M. Induction of Endogenous Bcl-xS through the Control of Bcl-x pre-mRNA Splicing by Antisense Oligonucleotides. Nat. Biotechnol. 1999, 17, 1097-1100.
121. Giles, R. V.; Spiller, D. G.; Clark, R.E.; Tidd, D. E. Antisense Morpholino Oligonucleotide Analog Induces Missplicing of C-Myc mRNA. Antisense Nucleic Acid DrugDev. 1999,9, 213-220.
122. Hudziak, R. M.; Summerton, J.; Weller, D. D.; Iversen, P. L. Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed Against C-Myc. Antisense Nucleic Acid Drug Dev.2000,10, 163-176.
123. Krawczak, M.; Reiss, J.; Cooper, D. N. The Mutational Spectrum of Single Base-Pair Substitutions in mRNA Splice Junctions of Human Genes: Causes and Consequences. Hum. Genet. 1992, 90, 41-54.
124. Kole, R., Modification of Alternative Splicing of PremRNA by Antisense Oligonucleotides. Applied Antisense Oligonucleotide Technology, ed. C. Stein and A. Krieg. Wiley Liss Inc.: New York, 1998.
125. Schwartz, E.; Benz, E. Thalassemia Syndromes. In Hematology: Basic Principles and Practice; Huffman, R. et al. ? ed. Churchill Livingston: New York, 1995, 586-610.
126. Lacerra, G.; Sierakowska, H.; Carestia, C.; Fucharoen, S.; Summerton, J.; Weller, D.; Kole, R. Restoration of Hemoglobin A Synthesis in Erythroid Cells From Peripheral Blood of Thalassemic Patients. Proc. Natl. Acad. Sei. U. S. A. 2000, 97, 9591-9596.
127. Schmajuk, G.; Sierakowska, H.; Kole, R. Antisense oligonucleotides with Different Backbones. Modification of Splicing Pathways and Efficacy of Uptake. J. Biol. Chem. 1999,274, 21783-21789.
128. Sierakowska, H.; Sambade, M. J.; Agrawal, S.; Kole, R. Repair of Thalassemic Human Beta-Globin mRNA in Mammalian Cells by Antisense Oligonucleotides. Proc. Natl. Acad. Sei. U. S. A. 1996, 93, 12840-12844.
129. Lewis, J.; Yang, B.; Kim, R.; Sierakowska, H.; Kole, R.; Smithies, O.; Maeda, N. A Common Human Beta Globin Splicing Mutation Modeled in Mice. Blood 1998, 91, 2152-2156.
130. Kang, S. H.; Cho, M. J.; Kole, R. Up-Regulation of Luciferase Gene Expression with Antisense Oligonucleotides: Implications and Applications in Functional Assay Development. Biochemistry 1998, 37, 6235-6239.
131. Abeliovich, D.; Lavon, I. P.; Lerer, L; Cohen, T.; Springer, C.; Avital, A.; Cutting, G. R. Screening for Five Mutations Detects 97% of Cystic Fibrosis (CF) Chromosomes and Predicts a Carrier Frequency of 1:29 in the Jewish Ashkenazi Population. Am. J. Hum. Genet. 1992,51, 951-956.
132. Friedman, K. J.; Kole, J.; Cohn, J. A.; Knowles, M. R.; Silverman, L. M.; Kole, R. Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) .Gene by Antisense Oligonucleotides. J. Biol. Chem. 1999, 274, 36193-36199.
133. Tsui, L. C. The Spectrum of Cystic Fibrosis Mutations. Trends Genet. 1992, 8, 392-398
134. Koenig, M.; Beggs, A. H.; Moyer, M.; Scherpf, S.; Heindrich, K.; Bettecken, T.; Meng, G.; Muller, C. R.; Lindlof, M.; Kaariainen, H.; et al. The Molecular Basis for Duchenne Versus Becker Muscular Dystrophy: Correlation of Severity with Type of Deletion. Am. J.Hum. Genet. 1989, 45, 498-506.
135. Mann, C. J.; Honeyman, K.; Cheng, A. J.; Ly, T.; Lloyd, F.; Fletcher, S.; Morgan, J. E.; Partridge, T. A.; Wilton, S. D. Antisense-Induced Exon Skipping and Synthesis of Dystrophin in the mdx Mouse. Proc. Natl. Acad. Sei. U. S. A. 2001, 98, 42-47.
136. Wilton, S. D.; Lloyd, F.; Carville, K.; Fletcher, S.; Honeyman, K.; Agrawal, S.; Kole, R. Specific Removal of the Nonsense Mutation from the mdx Dystrophin mRNA Using Antisense Oligonucleotides. Neuromuscul. Disord. 1999, 9, 330-338.
137. Goedert, M.; Spillantini, M. G.; Potier, M. C.; Ulrich, J.; Crowther, R. A. Cloning and Sequencing of the cDNA Encoding an Isoform of Microtubule-Associated Protein Tau Containing Four Tandem Repeats: Differential Expression of Tau Protein mRNAs in Human Brain. EMBO J. 1989, 8. 393-399.
138. Hutton, M. Missense and Splice Site Mutations in Tau Associated with FTDP-17: Multiple. Pathogenic Mechanisms. Neurology 2001, 56, S21-S25.
139. Kotsimbos, A. T.; Hamid, Q. IL-5 and IL-5 Receptor in Asthma. Mem. Inst. Oswaldo. Cruz. 1997, 92, 75-91.
140. Karras, J. G.; McKay, R. A.; Dean, N. M.; Monia, B. P. Deletion of Individual Exons and Induction of Soluble Murine Interleukin-5 Receptor-Alpha Chain Expression Through Antisense Oligonucleotide-Mediated Redirection of Pre-mRNA Splicing. Mol Pharmacol. 2000, 58, 380-387.
141. Zon, G. History of Antisense Drug Delivery In Antisense Research and Applications; Crooke, S.; LeBleu, B. Eds.; CRC Press, Inc: Boca Raton, 1993, 1-3.
142. Manoharan, M. 2′-Carbohydrate Modifications in Antisense Oligonucleotide Therapy: Importance of Conformation, Configuration and Conjugation. Biochim Biophys Acta 1999, 1489, 117-130.
143. Zhang, H.; Cook, J.; Nickel, J.; Yu, R.; Stecker, K.; Myers, K.; Dean, N. M. Reduction of Liver Fas Expression by an Antisense Oligonucleotide Protects Mice from Fulminant Hepatitis. Nat. Biotechnol. 2000, 18, 862-867.
144. Yu, R. Z.; Zhang, H.; Geary, R. S.; Graham, M.; Masarjian, L.; Lemonidis, K.; Crooke, R.; Dean, N. M.; Levin, A. A. Pharmacokinetics and Pharmacodynamics of an Antisense Phosphorothioate Oligonucleotide Targeting Fas mRNA in Mice. J. Pharmacol. Exp. Ther. 2001, 296. 388-395.
145. Griffey, R .H.; Monia, B. P.; Cummins, L. L.; Freier, S.; Greig, M. J.; Guinosso, C. J.; Lesnik, E.; Manalili, S. M.; Mohan, V.; Owens, S.; Ross, B. R.; Sasmor, H.; Wancewicz, E.; Weiler, K.; Wheeler, P. D.; Cook, P. D. 2′-0-Aminopropyl Ribonucleotides: a Zwitterionic Modification that Enhances the Exonuclease Resistance and Biological Activity of Antisense Oligonucleotides. J. Med. Chem. 1996,39, 5100-5109.
146. Orum, H.; Wengel, J. Locked Nucleic Acids: A Promising Molecular Family for Gene-Function Analysis and Antisense Drug Development Curr. Opin. Mol. Ther. 2001, 3, 239-243.
147. Obika, S.; Uneda, T.; Sugimoto, T.; Nanbu, D.; Minami, T.; Doi, T.; Imanishi, T. 2′-O,4′-C-Methylene Bridged Nucleic Acid (2′,4′-BNA):. Synthesis and Triplex-Forming Properties. Bioorg. Med. Chem. 2001, 9, 1001-1011.
148. Torigoe, H.; Hari, Y.; Sekiguchi, M.; Obika, S.; Imanishi, T. 2′-O,4′-C-Methylene Bridged Nucleic Acid Modification Promotes Pyrimidine Motif Triplex DNA Formation at Physiological pH. J. Biol. Chem. 2001, 270, 2354-2360.
149. Summerton, J. Morpholino Antisense Oligomers: the Case for an RNase H-Independent Structural Type. Biochim. Biophys. Acta 1999, 1489, 141-158.
150. Nasevicius, A.; Ekker, S. C. Effective Targeted Tene 'Knockdown' in Zebrafish. Nat. Genet. 2000, 26, 216-220.
151. Taylor, M. F.; Weller, D. D.; Kobzik, L. Effect of TNF-Alpha Antisense Oligomers on Cytokine Production by Primary Murine Alveolar Macrophages. Antisense Nucleic Acid Drug Dev. 1998, 8. 199-205.
152. Chen, J. K.; Weith, H. L.; Grevval, R. S.; Wang, G.; Cushman, M. Synthesis of Novel Phosphoramidite Reagents for the Attachment of Antisense Oligonucleotides to Various Regions of the Benzophenanthridine Ring System. Bioconjug. Chem. 1995,5, 473-482.
153. Gryaznov, S. M.; Lloyd, D. H.; Chen, J. K.; Schultz, R. G.; DeDionisio, L. A.; Ratmeyer, L.; Wilson, W. D. Oligonucleotide N3′->P5′ Phosphoramidates. Proc. Natl. Acad. Sei. U. S. A. 1995, 92, 5798-5802.
154. Gryaznov, S.; Skorski, T.; Cucco, C.; Nieborowska-Skorska, M.; Chiu, C. Y.; Lloyd, D.; Chen, J. K.; Koziolkiewicz, M.; Calabretta, B. Oligonucleotide N3′->P5′ phosphoramidates as antisense agents. Nucleic Acids Res. 1996,24, 1508-1514.
155. Gee, J. E.; Robbins, I.; van der Laan, A. C.; van Boom, J. H.; Colombier, C.; Leng, M.; Raible, A. M.; Nelson, J. S.; Lebleu, B. Assessment of High-Affinity Hybridization, RNase H Cleavage, and Covalent Linkage in Translation Arrest by Antisense Oligonucleotides. Antisense Nucleic Acid Drug Dev. 1998, 8, 103-311.
156. Wang, L.; Gryaznov, S.; Nerenberg, M. Inhibition of IL-6 in Mice by Anti-NF-KappaB Oligodeoxyribonucleotide N3′->oligodeoxyribon-nucleotide N3′-> P5′ Phosphoramidates Inflammation 1999, 23, 583-590.
157. Faria, M.; Spiller, D. G.; Dubertret, C.; Nelson, J. S.; White, M. R.; Scherman, D.; Helene, C.; Giovannangeli, C. Phosphoramidate Oligonucleotides as Potent Antisense Molecules in Cells and In Vivo. Nat. Biotechnol. 2001, 19, 40-44.
158. Larsen, H. J.; Bentin, T.; Nielsen, P. E. Antisense Properties of Peptide Nucleic Acid. Biochim. Biophys. Acta 1999, 1489. 159-166.
159. Hnatowich, D. J. Pharmacokinetic Considerations in the Development of Oligomers as Radiopharmaceuticals. Q. J. Nucl. Med. 1997, 41, 91-100.
160. Agrawal, S.; lyer, R. P. Modified Oligonucleotides as Therapeutic and Diagnostic Agents. Curr. Opin. Biotechnol. 1995, 6, 12-19.
161. Miller, P. S.; Cassidy, R. A.; Hamma, T.; Kondo, N.S. Studies on Anti-human Immunodeficiency Virus Oligonucleotides that have Alternating Methylphosphonate/Phosphodiester Linkages. Pharmacol. Ther. 2000, 85, 159-163.
162. Herdewijn, P. Heterocyclic Modifications of Oligonucleotides and Antisense Technology. Antisense Nucleic Acid Drug Dev. 2000,10, 297-310.
163. Flanagan, W. M.; Kothavale, A.; Wagner, R. W. Effects of Oligonucleotide Length, Mismatches and mRNA Levels on C-5 Propyne-modified Antisense Potency. Nucleic Acids Res. 1996, 24, 2936-2941.
164. Flanagan, W. M.; Wolf, J. J.; Olson, P.; Grant, D.; Lin, K. Y.; Wagner, R. W.; Matteucci, M. D. A Cytosine Analog that Confers Enhanced Potency to Antisense Oligonucleotides. Proc. Natl. Acad. Sei. U. S. A. 1999, 96, 3513-3518.
165. Balow, G.; Mohan, V.; Lesnik, E. A.; Johnston, J. F.; Monia, B. P.; Acevedo, O. L. Biophysical and Antisense Properties of Oligodeoxynucleotides Containing 7-Propynyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2′-deoxyadenosines. Nucleic Acids Res. 1998, 26, 3350-3357.
166. Lebedeva, I.; Benimetskaya, L.; Stein, C. A.; Vilenchik, M. Cellular Delivery of Antisense Oligonucleotides. Eur. J. Pharm. Biopharm. 2000, 50, 101-119.
167. DeLong, R. K.; Yoo, H.; Alahari, S. K.; Fisher, M.; Short, S. M.; Kang, S. H.; Kole, R.; Janout, V.; Regan, S. L.; Juliano, R. L. Novel Cationic Amphiphues as Delivery Agents for Antisense Oligonucleotides. Nucleic Acids Res. 1999, 27, 3334-3341.
168. Kang, S. H.; Zirbes, E. L.; Kole, R. Delivery of Antisense Oligonucleotides and Plasmid DNA with Various Carrier Agents. Antisense Nucleic Acid Drug Dev. 1999, 9, 497-505.
169. Yoo, H.; Juliano, R. L. Enhanced Delivery of Antisense Oligonucleotides with Fluorophore-Conjugated PAMAM Dendrimers. Nucleic Acids Res. 2000, 28, 4225-4231.
170. Jaaskelainen, I.; Peltola, S.; Honkakoski, P.; Monkkonen, J.; Urtti, A. A Lipid Carrier with a Membrane Active Component and a Small Complex Size are Required for Efficient Cellular Delivery of Anti-sense Phosphorothioate Oligonucleotides. Eur. J. Pharm. Sei. .2000,70, 187-193.
171. Junghans, M.; Kreuter, J.; Zimmer, A. Antisense Delivery Using Protamine-Oligonucleotide Particles. Nucleic Acids Res. 2000, 28, E45.
172. Lambert, G.; Fattal, E.; Couvreur, P. Nanoparticulate Systems for the Delivery of Antisense Oligonucleotides. Adv. Drug Deliv. Rev. 2001, 47, 99-112.
173. Delie, F.; Berton, M.; Allemann, E.; Gurny, R. Comparison of Two Methods of Encapsulation of an Oligonucleotide into Poly(D,L-lactic acid) Particles. Int. J. Pharm. 2001, 214, 25-30.
174. Benimetskaya, L.; Takle, G. B.; Vilenchik, M.; Lebedeva, I.; Miller, P.; Stein, C. A. Cationic Porphyrins: Novel Delivery Vehicles for Antisense Oligodeoxynucleotides. Nucleic Acids Res. 1998, 26, 5310-5317.
175. Freuion, L; Roche, A. C.; Monsigny, M.; Mayer, R. Delivery of Oligonucleotides into Mammalian Cells by Anionic Peptides: Comparison between Monomeric and Dimeric Peptides. Biochem. J.2001,354, 671-679.
176. Lindgren, M.; Hallbrink, M.; Prochiantz, A.; Langel, U. Cell-Penetrating Peptides. Trends Pharmacol. Sei. 2000,27, 99-103.
177. Derossi, D.; Chassaing, G.; Prochiantz, A. Trojan Peptides: The Penetrating System for Intracellular Delivery. Trends Cell Biol. 1998, 8, 84-87.
178. Astriab-Fisher, A.; Sergueev, D. S.; Fisher, M.; Shaw, B. R.; Juliano, R. L. Antisense.inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 2000, 60, 83-90.
179. Kole, R.; Sazani, P. Antisense Effects in the Cell Nucleus: Modification of Splicing. Curr. Opin. Molec. Therapeut. 2001, 3, 229-234.
180. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y. Arginine-Rich Peptides. An Abundant Source of Membrane-Permeable Peptides having Potential as Carriers for Intracellular Protein Delivery. J. Biol. Chem. 2001, 270, 5836-5840.
181. Bijsterbosch, M. K.; Rump, E. T.; De Vrueh, R. L.; Dorland, R.; van Veghel, R.; Tivel, K. L.; Biessen, E. A.; van Berkel, T. J.; Manoharan, M. Modulation of Plasma Protein Binding and In Vivo Liver Cell Uptake of Phosphorothioate Oligodeoxynucleotides by Cholesterol Conjugation. Nucleic Acids Res. 2000, 28, 2717-25.
182. Sazani, P.; Kang, S.H.; Maier, M.A.; Wei, C.; Dillman, J.; Summerton, J.; Manhoran, M. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 2001, 29, 3965-74.
183. Kalbfuss, B.; Mabon, S.A.; Misteli, T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonsim linked to chromosome 17. J. Biol. Chem. in press.